Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday

Immunic (NASDAQ:IMUX) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect Immunic to post earnings of ($0.1022) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

Immunic Stock Performance

Shares of Immunic stock opened at $0.88 on Thursday. The firm has a fifty day moving average of $0.65 and a two-hundred day moving average of $0.76. Immunic has a one year low of $0.51 and a one year high of $1.39. The company has a market cap of $105.51 million, a P/E ratio of -1.06 and a beta of 1.58.

Wall Street Analysts Forecast Growth

IMUX has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Immunic in a research report on Monday, February 9th. Brookline Capital Acquisition raised Immunic to a “strong-buy” rating in a research note on Tuesday, February 3rd. Roth Mkm assumed coverage on Immunic in a report on Friday, November 7th. They set a “buy” rating and a $3.00 price objective for the company. Finally, Chardan Capital raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Immunic presently has an average rating of “Buy” and an average price target of $6.60.

Institutional Trading of Immunic

Several hedge funds have recently made changes to their positions in the stock. Qube Research & Technologies Ltd acquired a new position in shares of Immunic during the third quarter valued at $29,000. Two Sigma Investments LP acquired a new stake in Immunic during the third quarter valued at approximately $52,000. Virtu Financial LLC acquired a new stake in Immunic during the 3rd quarter valued at $99,000. XTX Topco Ltd purchased a new stake in shares of Immunic in the fourth quarter worth approximately $120,000. Finally, Jane Street Group LLC boosted its position in Immunic by 46.8% during the fourth quarter. Jane Street Group LLC now owns 286,677 shares of the company’s stock valued at $153,000 after purchasing an additional 91,346 shares during the last quarter. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.